These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 7917775)
21. Human hepatic cytochrome P-450 composition as probed by in vitro microsomal metabolism of warfarin. Kaminsky LS; Dunbar DA; Wang PP; Beaune P; Larrey D; Guengerich FP; Schnellmann RG; Sipes IG Drug Metab Dispos; 1984; 12(4):470-7. PubMed ID: 6148215 [TBL] [Abstract][Full Text] [Related]
22. Warfarin Metabolites in Patients Following Cardiac Valve Implantation: A Contribution of Clinical and Genetic Factors. Bryk A; Wypasek E; Awsiuk M; Maj D; Undas A Cardiovasc Drugs Ther; 2015 Jun; 29(3):257-64. PubMed ID: 25986145 [TBL] [Abstract][Full Text] [Related]
23. Novel multi-mode ultra performance liquid chromatography-tandem mass spectrometry assay for profiling enantiomeric hydroxywarfarins and warfarin in human plasma. Jones DR; Boysen G; Miller GP J Chromatogr B Analyt Technol Biomed Life Sci; 2011 May; 879(15-16):1056-62. PubMed ID: 21470921 [TBL] [Abstract][Full Text] [Related]
24. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Takahashi H; Ishikawa S; Nomoto S; Nishigaki Y; Ando F; Kashima T; Kimura S; Kanamori M; Echizen H Clin Pharmacol Ther; 2000 Nov; 68(5):541-55. PubMed ID: 11103757 [TBL] [Abstract][Full Text] [Related]
25. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Jiang X; Williams KM; Liauw WS; Ammit AJ; Roufogalis BD; Duke CC; Day RO; McLachlan AJ Br J Clin Pharmacol; 2004 May; 57(5):592-9. PubMed ID: 15089812 [TBL] [Abstract][Full Text] [Related]
26. Discovery of Novel Reductive Elimination Pathway for 10-Hydroxywarfarin. Pouncey DL; Barnette DA; Sinnott RW; Phillips SJ; Flynn NR; Hendrickson HP; Swamidass SJ; Miller GP Front Pharmacol; 2021; 12():805133. PubMed ID: 35095511 [TBL] [Abstract][Full Text] [Related]
27. High clearance of (S)-warfarin in a warfarin-resistant subject. Hallak HO; Wedlund PJ; Modi MW; Patel IH; Lewis GL; Woodruff B; Trowbridge AA Br J Clin Pharmacol; 1993 Mar; 35(3):327-30. PubMed ID: 8471414 [TBL] [Abstract][Full Text] [Related]
28. Effect of rutin on warfarin anticoagulation and pharmacokinetics of warfarin enantiomers in rats. Chan E; Hegde A; Chen X J Pharm Pharmacol; 2009 Apr; 61(4):451-8. PubMed ID: 19298691 [TBL] [Abstract][Full Text] [Related]
29. Regioselectivity significantly impacts microsomal glucuronidation efficiency of R/S-6, 7-, and 8-hydroxywarfarin. Kim SY; Jones DR; Kang JY; Yun CH; Miller GP Xenobiotica; 2019 Apr; 49(4):397-403. PubMed ID: 29543105 [TBL] [Abstract][Full Text] [Related]
30. A chiral HPLC-MS/MS method for simultaneous quantification of warfarin enantiomers and its major hydroxylation metabolites of CYP2C9 and CYP3A4 in human plasma. Ju W; Peng K; Yang S; Sun H; Sampson M; Wang MZ Austin J Anal Pharm Chem; 2014; 1(2):. PubMed ID: 26161443 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of warfarin enantiomers: a search for intrasubject correlations. Wingard LB; O'Reilly RA; Levy G Clin Pharmacol Ther; 1978 Feb; 23(2):212-7. PubMed ID: 620483 [TBL] [Abstract][Full Text] [Related]
32. Microbial models of mammalian metabolism: stereoselective metabolism of warfarin in the fungus Cunninghamella elegans. Wong YW; Davis PJ Pharm Res; 1989 Nov; 6(11):982-7. PubMed ID: 2594692 [TBL] [Abstract][Full Text] [Related]
33. Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. Lewis RJ; Trager WF; Chan KK; Breckenridge A; Orme M; Roland M; Schary W J Clin Invest; 1974 Jun; 53(6):1607-17. PubMed ID: 4830225 [TBL] [Abstract][Full Text] [Related]
34. The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose. Herman D; Locatelli I; Grabnar I; Peternel P; Stegnar M; Lainscak M; Mrhar A; Breskvar K; Dolzan V Eur J Clin Pharmacol; 2006 Apr; 62(4):291-6. PubMed ID: 16552506 [TBL] [Abstract][Full Text] [Related]
35. Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. Hermans JJ; Thijssen HH Br J Pharmacol; 1993 Sep; 110(1):482-90. PubMed ID: 8220911 [TBL] [Abstract][Full Text] [Related]
36. Determination of warfarin enantiomers and hydroxylated metabolites in human blood plasma by liquid chromatography with achiral and chiral separation. Locatelli I; Kmetec V; Mrhar A; Grabnar I J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Apr; 818(2):191-8. PubMed ID: 15734158 [TBL] [Abstract][Full Text] [Related]
37. Disposition of drugs in cystic fibrosis. V. In vivo CYP2C9 activity as probed by (S)-warfarin is not enhanced in cystic fibrosis. O'Sullivan TA; Wang JP; Unadkat JD; al-Habet SM; Trager WF; Smith AL; McNamara S; Aitken ML Clin Pharmacol Ther; 1993 Sep; 54(3):323-8. PubMed ID: 8375128 [TBL] [Abstract][Full Text] [Related]
38. Multiple UDP-glucuronosyltransferases in human liver microsomes glucuronidate both R- and S-7-hydroxywarfarin into two metabolites. Pugh CP; Pouncey DL; Hartman JH; Nshimiyimana R; Desrochers LP; Goodwin TE; Boysen G; Miller GP Arch Biochem Biophys; 2014 Dec; 564():244-53. PubMed ID: 25447818 [TBL] [Abstract][Full Text] [Related]
39. The influence of (R)- and (S)-warfarin, vitamin K and vitamin K epoxide upon warfarin anticoagulation. Kamali F; Edwards C; Butler TJ; Wynne HA Thromb Haemost; 2000 Jul; 84(1):39-42. PubMed ID: 10928467 [TBL] [Abstract][Full Text] [Related]
40. Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations. Banfield C; O'Reilly R; Chan E; Rowland M Br J Clin Pharmacol; 1983 Dec; 16(6):669-75. PubMed ID: 6661352 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]